@article{MTMT:2870670,
	title = {Health status and quality of life in patients with psoriasis: an Iranian cross-sectional survey},
	url = {https://m2.mtmt.hu/api/publication/2870670},
	author = {Moradi, Mahshid and Rencz, Fanni and Brodszky, Valentin and Moradi, A and Balogh, Orsolya and Gulácsi, László},
	journal-iso = {ARCH IRAN MED},
	journal = {ARCHIVES OF IRANIAN MEDICINE},
	volume = {18},
	unique-id = {2870670},
	issn = {1029-2977},
	abstract = {BACKGROUND: Psoriasis has a significant negative impact on patients' health-related quality of life (HRQOL). This study aims to evaluate HRQOL of adult patients with psoriasis in Iran, and explore the relationship between general and disease-specific outcome measures in psoriasis. METHODS: Between May and August 2013, a cross-sectional questionnaire survey of consecutive outpatients was conducted at a single clinic in Shiraz, Iran. HRQOL was assessed by the general measure EuroQol 5 dimensions (EQ-5D), visual analogue scale (EQ VAS), and the disease-specific Dermatology Life Quality Index (DLQI). Disease severity was measured by the Psoriasis Area and Severity Index (PASI). RESULTS: Sixty-two patients (76% males) completed the questionnaire with a mean age (SD) of 40.4 (17.5) years. Overall, 39% of the patients used only topical and 48% received systemic non-biological therapy in the past 12 months. Median EQ-5D, EQ VAS, DLQI and PASI scores were 0.73, 60, 8 and 11.75, respectively. Out of the 62 patients, 18%, 26%, 28%, 63%, and 63% reported some or severe problem in mobility, self-care, usual activities, pain/discomfort and anxiety/depression, respectively. EQ-5D and EQ VAS correlated moderately with DLQI (rs = -0.44 for both, p < 0.001), but only EQ VAS correlated significantly with PASI (rs = -0.31, p < 0.01). CONCLUSION: This is the first study from Iran that assesses HRQOL in adult patients with psoriasis by EQ-5D and EQ VAS. Reduction in general HRQOL measured with EQ-5D and EQ-VAS is considerable, mostly in anxiety/depression and pain/discomfort dimensions. EQ-5D scores evaluated in this study provide country-specific data for economic evaluations.},
	year = {2015},
	eissn = {1735-3947},
	pages = {153-159}
}

@article{MTMT:2791920,
	title = {Moderate to severe psoriasis patients' subjective future expectations regarding health-related quality of life and longevity.},
	url = {https://m2.mtmt.hu/api/publication/2791920},
	author = {Rencz, Fanni and Holló, Péter and Kárpáti, Sarolta and Péntek, Márta and Remenyik, Éva and Szegedi, Andrea and Balogh, Orsolya and Heredi, E and Herszényi, Krisztina and Jókai, Hajnalka and Brodszky, Valentin and Gulácsi, László},
	doi = {10.1111/jdv.12884},
	journal-iso = {J EUR ACAD DERMATOL},
	journal = {JOURNAL OF THE EUROPEAN ACADEMY OF DERMATOLOGY AND VENEREOLOGY},
	volume = {29},
	unique-id = {2791920},
	issn = {0926-9959},
	abstract = {BACKGROUND: Unrealistic expectations regarding treatments and clinical outcomes may lead to disappointment about therapy and sub-optimal compliance; nonetheless, these expectations have not been studied in psoriasis patients yet. OBJECTIVE: To evaluate psoriasis patients' subjective future expectations regarding health-related quality of life (HRQOL) and life expectancy, and to explore clinical features associated with under- or overestimating behaviour. METHODS: A cross-sectional questionnaire survey of consecutive adult patients with moderate to severe psoriasis was conducted. HRQOL expectations were recorded by applying the EQ-5D descriptive system for 6 months ahead and for future ages of 60, 70, 80 and 90 respectively. RESULTS: In total, 167 patients (71% males) were included in the analysis with mean age of 50.4 +/- 12.4 years and mean EQ-5D score of 0.71 +/- 0.30. Overall 65% had chronic plaque psoriasis, 35% nail psoriasis, 35% scalp involvement, 29% psoriatic arthritis, 9% inverse psoriasis and 5% palmoplantar psoriasis respectively (combinations occurred). Participants expected 0.1 +/- 0.23 mean improvement in EQ-5D within 6 months (P < 0.001) that achieves the minimum clinically important difference. Overall 37% expected improvement and 13% decline; however, 49% expected no changes in any of the five dimensions of EQ-5D within 6 months. Female gender, inverse or palmoplantar involvement and more severe psoriasis were likely associated with higher expectations. Patients at the initiation of their first biological at the time of the survey expected 0.18 +/- 0.24 increase that seems to be realistic compared to the EQ-5D utility gain achieved in randomized controlled trials. Males expected by 2.7 +/- 11.1 more, while females expected by 5.2 +/- 9.3 less life years compared to the average statistical gender- and age-matched life expectancy (P < 0.05). Patients who expected to be alive at ages of 60, 70, 80 and 90 scored their future EQ-5D at ages of 60 to 90: 0.59 +/- 0.46, 0.48 +/- 0.41, 0.42 +/- 0.41 and 0.22 +/- 0.47 respectively. CONCLUSION: Our findings highlight the importance of exploring expectations that might help to increase patients' compliance.},
	year = {2015},
	eissn = {1468-3083},
	pages = {1398-1405},
	orcid-numbers = {Holló, Péter/0000-0002-0744-8989; Kárpáti, Sarolta/0000-0002-8472-0712; Jókai, Hajnalka/0000-0002-5940-2261}
}

@mastersthesis{MTMT:2805475,
	title = {Economic consideration of the implementation of biotechnological therapies in chronic diseases = Krónikus betegségek biológiai terápiájának alkalmazásával kapcsolatos gazdasági megfontolások},
	url = {https://m2.mtmt.hu/api/publication/2805475},
	author = {Balogh, Orsolya},
	doi = {10.14267/phd.2014072},
	unique-id = {2805475},
	year = {2014}
}

@article{MTMT:2782926,
	title = {Disease burden of psoriasis associated with psoriatic arthritis in Hungary [Arthritis psoriaticával társuló középsúlyos és súlyos psoriasis betegségterhe Magyarországon]},
	url = {https://m2.mtmt.hu/api/publication/2782926},
	author = {Rencz, Fanni and Brodszky, Valentin and Péntek, Márta and Balogh, Orsolya and Remenyik, Éva and Szegedi, Andrea and Holló, Péter and Kárpáti, Sarolta and Jókai, Hajnalka and Herszényi, Krisztina and Heredi, E and Szántó, Sándor Zoltán and Gulácsi, László},
	doi = {10.1556/OH.2014.30044},
	journal-iso = {ORV HETIL},
	journal = {ORVOSI HETILAP},
	volume = {155},
	unique-id = {2782926},
	issn = {0030-6002},
	abstract = {INTRODUCTION: Psoriasis is a frequent, chronic, systemic immune-mediated disease mainly affecting the skin and joints. AIM: To assess health related quality of life and cost-of-illness in moderate to severe psoriasis associated with psoriatic arthritis. METHOD: A cross-sectional questionnaire survey was conducted at two academic dermatology clinics in Hungary. RESULTS: Fifty-seven patients (65% males) completed the survey with a mean age of 54.3+/-11.6 years and mean EQ-5D score of 0.48+/-0.4. Mean annual total cost was euro8,977 per patient, of which 71% occurred due to biological therapy and 21% were indirect costs, respectively. Permanent work disability due to psoriasis accounted for euro1,775 (95% of the indirect costs). Per patient costs of subgroups not receiving systemic therapy (21%), traditional systemic therapy (32%), and biological systemic therapy (47%) amounted to the sum of euro1,729, euro1,799, and euro16,983, respectively. CONCLUSIONS: Patients on biological therapy showed significantly better health related quality of life. As for health economics, the efficacy of systemic treatments is appropriate to be assessed together in patients with moderate to severe psoriasis associated with psoriatic arthritis, since actual health gain might exceed that reported in psoriasis or psoriatic arthritis separately. Orv. Hetil., 2014, 155(48), 1913-1921.},
	year = {2014},
	eissn = {1788-6120},
	pages = {1913-1921},
	orcid-numbers = {Holló, Péter/0000-0002-0744-8989; Kárpáti, Sarolta/0000-0002-8472-0712; Jókai, Hajnalka/0000-0002-5940-2261; Szántó, Sándor Zoltán/0000-0001-5030-6292}
}

@article{MTMT:2778178,
	title = {Budget Impact Analysis Of Biosimilar Infliximab For The Treatment Of Crohn’s Disease In Six Central Eastern European Countries},
	url = {https://m2.mtmt.hu/api/publication/2778178},
	author = {Brodszky, Valentin and Gulácsi, László and Balogh, Orsolya and Baji, Petra and Rencz, Fanni and Péntek, Márta},
	journal-iso = {VALUE HEALTH},
	journal = {VALUE IN HEALTH},
	volume = {17},
	unique-id = {2778178},
	issn = {1098-3015},
	year = {2014},
	eissn = {1524-4733},
	pages = {A364-A364}
}

@inbook{MTMT:2727973,
	title = {Clinical efficacy and safety of biologicals in Psoriatic Arthritis},
	url = {https://m2.mtmt.hu/api/publication/2727973},
	author = {Balogh, Orsolya},
	booktitle = {Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Psoriatic Arthritis},
	unique-id = {2727973},
	year = {2014},
	pages = {13-38}
}

@inbook{MTMT:2727963,
	title = {Epidemiology, clinical characteristics and health status assessment in Psoriatic Arthritis},
	url = {https://m2.mtmt.hu/api/publication/2727963},
	author = {Balogh, Orsolya and Brodszky, Valentin},
	booktitle = {Systematic review and analysis of evidences on clinical efficacy and cost-effectiveness of biological drugs for the treatment of Psoriatic Arthritis},
	unique-id = {2727963},
	year = {2014},
	pages = {1-12}
}

@article{MTMT:2590788,
	title = {Budget impact analysis of biosimilar infliximab (CT-P13) for the treatment of rheumatoid arthritis in six Central and Eastern European countries.},
	url = {https://m2.mtmt.hu/api/publication/2590788},
	author = {Brodszky, Valentin and Baji, Petra and Balogh, Orsolya and Péntek, Márta},
	doi = {10.1007/s10198-014-0595-3},
	journal-iso = {EUR J HEALTH ECON},
	journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
	volume = {15},
	unique-id = {2590788},
	issn = {1618-7598},
	abstract = {The first biosimilar monoclonal antibody (infliximab, CT-P13) was registered by the European Medicines Agency in 2013 for the treatment of several inflammatory conditions including rheumatoid arthritis (RA). Biosimilar infliximab is first being marketed in the Central and Eastern European countries. This paper presents the estimated budget impact of the introduction of biosimilar infliximab in RA over a 3-year time period in six selected countries, namely Bulgaria, the Czech Republic, Hungary, Poland, Romania and Slovakia. A prevalence-based model was constructed for budget impact analysis. Two scenarios were compared to the reference scenario (RSc) where no biosimilar infliximab is available: biosimilar scenario 1 (BSc1), where interchanging the originator infliximab with biosimilar infliximab is disallowed, and only patients who start new biological therapy are allowed to use biosimilar infliximab; as well as biosimilar scenario 2 (BSc2), where interchanging the originator infliximab with biosimilar infliximab is allowed, and 80 % of patients treated with originator infliximab are interchanged to biosimilar infliximab. Compared to the RSc, the net savings are estimated to be 15.3 or 20.8 M in BSc1 and BSc2, respectively, over the 3 years. If budget savings were spent on reimbursement of additional biosimilar infliximab treatment, approximately 1,200 or 1,800 more patients could be treated in the six countries within 3 years in the two biosimilar scenarios, respectively. The actual saving is most sensitive to the assumption of the acquisition cost of the biosimilar drug and to the initial number of patients treated with biological therapy. The study focused on one indication (RA) and demonstrated that the introduction of biosimilar infliximab can lead to substantial budget savings in health care budgets. Further savings are expected for other indications where biosimilar medicines are implemented.},
	year = {2014},
	eissn = {1618-7601},
	pages = {65-71}
}

@article{MTMT:2590787,
	title = {Exploring the relationship between EQ-5D, DLQI and PASI, and mapping EQ-5D utilities: a cross-sectional study in psoriasis from Hungary},
	url = {https://m2.mtmt.hu/api/publication/2590787},
	author = {Heredi, E and Rencz, Fanni and Balogh, Orsolya and Gulácsi, László and Herszényi, Krisztina and Holló, Péter and Jókai, Hajnalka and Kárpáti, Sarolta and Péntek, Márta and Remenyik, Éva and Szegedi, Andrea and Brodszky, Valentin},
	doi = {10.1007/s10198-014-0600-x},
	journal-iso = {EUR J HEALTH ECON},
	journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
	volume = {15},
	unique-id = {2590787},
	issn = {1618-7598},
	abstract = {BACKGROUND: There is a growing interest in policy making for using utility measures and identifying algorithms to convert disease-specific measures into utilities. OBJECTIVES: To analyse the relationship between EQ-5D, Dermatology Life Quality Index (DLQI) and Psoriasis Area and Severity Index (PASI) in psoriasis. To transform DLQI scores, and key clinical, demographic and health service utilisation variables into utilities. METHODS: A cross-sectional questionnaire survey of 200 consecutive adult patients with moderate to severe psoriasis was carried out in two Hungarian university clinics. The relationship between the outcome measures were analysed with correlations and with the known-groups method. Bivariate and multivariate regression algorithms on EQ-5D scores were formulated. RESULTS: The mean age of respondents was 51 years (SD = 12.9), 68.5 % were male, and 51.5 % received biological therapy. Median EQ-5D, DLQI, and PASI scores were 0.73, 3.0, and 3.45, respectively. EQ-5D showed a moderate correlation with the DLQI and with the PASI (r s = -0.48 and -0.43, p < 0.05). Strong correlation was found between DLQI and PASI (r s = 0.81, p < 0.05). DLQI and PASI discriminated better among groups categorised by the localisation of the lesions than EQ-5D. Presence of psoriasis on the neck and/or decolletage was associated with the greatest health related quality of life (HRQOL) impairment. Ten variables were incorporated in a multivariate algorithm that accounted for 48.8 % of EQ-5D variance (ANOVA p < 0.001). CONCLUSIONS: This study provided the first evidence that patients with visible psoriatic lesions have significantly worse HRQOL compared to those with non-visible lesions, measured not only with DLQI but also with EQ-5D. In addition to demographic and clinical variables, our model included health service utilisation variables related to psoriasis, and explained higher proportion of EQ-5D variance than any previous findings in the literature.},
	year = {2014},
	eissn = {1618-7601},
	pages = {111-119},
	orcid-numbers = {Holló, Péter/0000-0002-0744-8989; Jókai, Hajnalka/0000-0002-5940-2261; Kárpáti, Sarolta/0000-0002-8472-0712}
}

@article{MTMT:2590786,
	title = {Cost-of-illness in patients with moderate to severe psoriasis: a cross-sectional survey in Hungarian dermatological centres.},
	url = {https://m2.mtmt.hu/api/publication/2590786},
	author = {Balogh, Orsolya and Brodszky, Valentin and Gulácsi, László and Heredi, E and Herszényi, Krisztina and Jókai, Hajnalka and Kárpáti, Sarolta and Baji, Petra and Remenyik, Éva and Szegedi, Andrea and Holló, Péter},
	doi = {10.1007/s10198-014-0599-z},
	journal-iso = {EUR J HEALTH ECON},
	journal = {EUROPEAN JOURNAL OF HEALTH ECONOMICS},
	volume = {15},
	unique-id = {2590786},
	issn = {1618-7598},
	abstract = {BACKGROUND: Despite the widespread availability of biological drugs in psoriasis, there is a shortage of disease burden studies. OBJECTIVES: To assess the cost-of-illness and quality of life of patients with moderate to severe psoriasis in Hungary. METHODS: Consecutive patients with Psoriasis Area and Severity Index (PASI) > 10 and Dermatology Life Quality Index (DLQI) > 10, or treated with traditional systemic (TST) or biological systemic treatment (BST) were included. Demographic data, clinical characteristics, psoriasis related medication, health care utilizations and employment status in the previous 12 months were recorded. Costing was performed from the societal perspective applying the human capital approach. Quality of life was assessed using DLQI and EQ-5D measures. RESULTS: Two-hundred patients were involved (females 32 %) with a mean age of 51 (SD 13) years, 103 (52 %) patients were on BST. Mean PASI, DLQI and EQ-5D scores were 8 (SD 10), 6 (SD 7) and 0.69 (SD 0.3), respectively. The mean total cost was 9,254/patient/year (SD 8,502) with direct costs accounting for 86 %. The main cost driver was BST (mean 7,339/patient/year). Total costs differed significantly across treatment subgroups, mean (SD): no systemic therapy 2,186 (4,165), TST 2,388 (4,106) and BST 15,790 (6,016) (p < 0,001). Patients with BST had better PASI and DLQI scores (p < 0.01) than the other two subgroups. CONCLUSIONS: Patients with biological treatment have a significantly better quality of life and higher total costs than patients with or without traditional systemic treatment. Our study is the largest in Europe and the first in the CEE region that provides cost-of-illness data in psoriasis involving patients with BST.},
	year = {2014},
	eissn = {1618-7601},
	pages = {101-109},
	orcid-numbers = {Jókai, Hajnalka/0000-0002-5940-2261; Kárpáti, Sarolta/0000-0002-8472-0712; Holló, Péter/0000-0002-0744-8989}
}